Delving into the Latest Updates on AD-6626 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

AD 6626

Target

ALDH2

Action

stimulants

Mechanism

ALDH2 stimulants(Aldehyde dehydrogenase stimulants)

Therapeutic Areas

Other DiseasesCongenital DisordersEndocrinology and Metabolic Disease+ [1]

Active Indication-

Inactive Indication

AlcoholismFanconi Anemia

Originator Organization

Stanford University

Active Organization-

Inactive Organization

Stanford University

Aldea

Aldea Pharmaceuticals, Inc.

Drug Highest PhasePendingPhase 1

First Approval Date-

Regulation-

Login to view timeline

A Single-Center, 2-Part, Randomized, Double-Blind, Placebo-Controlled, Single-dose, Dose Escalation Study to Evaluate the Safety/Tolerability and Pharmacokinetics of a Single Dose of AD-6626 Administered Orally to Normal, Healthy Volunteers in Part A and the Safety/Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of a Single Oral Dose of AD-6626 Followed by Alcohol Administration in Normal, Healthy Volunteers With the Aldehyde Dehydrogenase 2 (ALDH2)*1/*1 (Wild Type) or ALDH2*1/*2 (Heterozygous) Genetic Variant in Part B

Start Date20 Jan 2015

Sponsor / Collaborator

Nucleus Network

[+1]

ACTRN12614001333606

/ RecruitingNot Applicable

A Single-Center, 2-Part, Randomized, Double-Blind, Placebo Controlled, Single-Dose, Dose Escalation Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of AD-6626 Administered Intravenously to Normal, Healthy Volunteers (NHVs) Without Alcohol Administration in Part A and to NHVs and Subjects Heterozygous for the Aldehyde Dehydrogenase 2*1/*2 Genetic Variant With Alcohol Administration in Part B

Start Date18 Dec 2014

Sponsor / Collaborator

Aldea Pharmaceuticals, Inc.

100 Clinical Results associated with AD-6626

Login to view more data

100 Translational Medicine associated with AD-6626

Login to view more data

100 Patents (Medical) associated with AD-6626

Login to view more data

100 Deals associated with AD-6626

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Alcoholism	Phase 1	Australia	Aldea Pharmaceuticals, Inc.	-
Alcoholism	Phase 1	-	Aldea	-
Alcoholism	Phase 1	-	Stanford University	-
Fanconi Anemia	Discovery	United States	Aldea Pharmaceuticals, Inc.	-